Test Price
2,800 AED✅ Home Collection Available
IDH1 Exon 4 Mutation Analysis (NGS) in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity for IDH1 exon 4 mutations via ISO 9001:2015 accredited NGS processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM for standard peripheral blood specimens.
Post-Test Guidance: Complimentary telephonic clinical result interpretation from a DHA-licensed consultant medical geneticist.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This test detects clinically actionable single-nucleotide variants and small insertions/deletions in exon 4 of the IDH1 gene using high-sensitivity Next-Generation Sequencing (NGS). It guides precision oncology decisions in gliomas, acute myeloid leukemia, and cholangiocarcinoma by identifying mutations (most commonly R132H, R132C, R132G, R132S, R132L) that influence prognosis and targeted therapy selection (e.g., ivosidenib).
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | Detects variants at <1% allele frequency | Limit of detection ~15-20% VAF |
| Methodology | Massively parallel NGS (Illumina®) with targeted enrichment | Single-amplicon capillary sequencing |
| Turnaround Time | 3-4 Weeks (comprehensive QA) | 7-10 Days |
| Regulatory Adherence | DHA/MOHAP Standard, ISO 9001:2015 | Variable |
Physician Insight & Safety Protocols
“An IDH1 mutation result must be interpreted within the full clinical context—imaging, histology, and other biomarkers. A positive finding is not a standalone cancer diagnosis, and a negative result does not exclude malignancy. Our genetic counselling team provides empathetic, evidence-based guidance throughout your journey.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License No: 9294403
⚠️ Medication Advisory
Do not discontinue any prescribed medication, including chemotherapy or targeted therapy, without direct consultation with your treating oncologist. Test results may influence treatment plans but must be reviewed by your physician before any changes.
Exclusion Criteria & Emergency Red Flags
- Active systemic infection or febrile illness at time of blood draw.
- Inability to provide informed consent; for minors, legal guardian consent is mandatory per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Known allergy to antiseptics or adhesive tapes used in phlebotomy.
- Emergency: Seek immediate medical care if you experience sudden severe headache, vision changes, uncontrolled bleeding, or acute confusion—these require urgent evaluation independent of this test.
- This test is not validated for prenatal screening or as a standalone screening for healthy individuals without clinical indication.
Patient FAQ & Clinical Guidance
1. What is the clinical significance of an IDH1 mutation?
IDH1 mutations are key driver alterations in certain cancers (gliomas, AML, cholangiocarcinoma). They help classify tumors, predict response to targeted therapies such as ivosidenib, and provide prognostic information for treatment planning.
2. How long does it take to get results?
Standard turnaround time is 3 to 4 weeks. This includes library preparation, deep sequencing, bioinformatics analysis, and a rigorous clinical interpretation aligned with DHA guidelines.
3. Can this test be performed on children?
Yes, but written informed consent from a legal guardian is required under Federal Decree-Law No. 4 of 2016 on Medical Liability. A pre-test genetic counselling session is also mandatory before specimen collection.
4. What sample is needed?
A standard peripheral blood sample (3-5 ml in an EDTA tube) is sufficient. For patients with known solid tumors, an FFPE tissue block may also be accepted upon oncologist request.
UAE Regulatory & Data Privacy Adherence
Data Protection: All genetic data is processed in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Clinical Safety: Patient consent and safety protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your results are encrypted and accessible only to your designated healthcare provider.
Clinical & Logistical Metadata
| Test Name | IDH1 Exon 4 Mutation Analysis (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks (21–28 business days) |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or FFPE tissue block |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina® platform, targeted enrichment for IDH1 exon 4 |
| ICD-10-CM Code | C71.9 (Malignant neoplasm of brain, unspecified) |
| LOINC Code | 91783-8 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians